Tropomyosin pp 158-167 | Cite as

Tropomyosins in Human Diseases: Ulcerative Colitis

  • Kiron M. Das
  • Manisha Bajpai
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 644)


Ulcerative colitis (UC) is a form of chronic inflammatory bowel disease (IBD) that almost always affects the rectal mucosa and variable length of the colon in continuity and at times mucosa of the entire colon. It is not caused by any specific pathogen. Genetics, environmental factors and altered immune responses to dietary macromolecules, colonic bacteria and cellular proteins have been implicated in the pathogenesis of UC. Autoimmune response against cytoskeletal, microfilament protein tropomyosin (Tm) seems to play an important role in the pathogenesis of UC. The predominant colonic epithelial Tm isoform, hTm5, can induce both humoral (B-cells) and cellular (T-cells) response in patients with UC. Such responses are not seen in normal subjects and disease control subjects, such as patients with Crohn’s disease (CD, another type of IBD) and patients with lupus. A novel observation that hTm5 is expressed on colon epithelial cell surface but not on small intestinal epithelial cells provides evidence for presentation to immune effector cells. This surface expression of hTm5 seems to be facilitated by a colon epithelial cell membrance associated protein, CEP, that acts as a chaperone for the trans-migration of hTm5 to the surface and both hTm5 and CEP are then released outside the cell. Both CEP and hTm5 expression are increased with pro-inflammatory cytokine, such as γ-interferon. hTm5 expression in UC mucosa is also significantly increased compared to normal. Finally, autoantibodies against hTm5 observed both in circulation and in the colon mucosa of patients with UC are pathogenic causing colon epithelial cell destruction by antibody and complement mediated cytolysis.


Ulcerative Colitis Primary Sclerosing Cholangitis Pyoderma Gangrenosum Biliary Epithelial Cell Extraintestinal Manifestation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998; 115:182–205.PubMedCrossRefGoogle Scholar
  2. 2.
    MacDonald TT, Monteleone G. Immunity, inflammation and allergy in the gut. Science 2005; 307:1920–1925.PubMedCrossRefGoogle Scholar
  3. 3.
    Fuss IJ, Neurath M, Boirivant M et al. Disparate CD4+lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn’s disease LP cells manifest increased secretion of IFN-γ, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 1996; 157:1261–1270.PubMedGoogle Scholar
  4. 4.
    Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics and prebiotics. Gastroenterology 2004; 126:1620–1633.PubMedCrossRefGoogle Scholar
  5. 5.
    Ahmad T, Marshall S, Jewell D. Genotype-based phenotyping heralds a new taxonomy for inflammatory bowel disease. Curr Opin Gastroenterol 2003; 19:327–335.PubMedCrossRefGoogle Scholar
  6. 6.
    Bonen DK, Cho JH. The genetics of inflammatory bowel disease. Gastroenterology 2003; 124:521–536.PubMedCrossRefGoogle Scholar
  7. 7.
    Satsangi J, Morecroft J, Shah NB et al. Genetics of inflammatory bowel disease: scientific and clinical implications. Best Pract Res Clin Gastroenterol 2003; 17:3–18.PubMedCrossRefGoogle Scholar
  8. 8.
    Schwab M, Schaeffeler E, Marx C et al. Association between the C3435T MDRI gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology 2003; 124:26–33.PubMedCrossRefGoogle Scholar
  9. 9.
    Brandtzaeg P. Autoimmunity and ulcerative colitis: Can two enigmas make sense together? Gastroenterology 1995; 109:3007–312.CrossRefGoogle Scholar
  10. 10.
    Broberger O, Perlmann P. Autoantibodies in human ulcerative colitis. J Exp Med 1959; 110:657–674.PubMedCrossRefGoogle Scholar
  11. 11.
    Fiocchi C, Roche JK, Michener WM. High prevalence of antibodies to intestinal epithelial antigens in patients with inflammatory bowel disease and their relatives. Ann Intern Med 1989; 110:786–794.PubMedGoogle Scholar
  12. 12.
    Yonamine Y, Watanabe M, Kinjo F et al. Generation of MHC class 1-restricted cytotoxic T-cell lines and clones against colonic epithelial cells from ulcerative colitis. J Clin Immunol 1999; 110:786–794.Google Scholar
  13. 13.
    Dasgupta A, Ramaswamy K, Giraldo J et al. Colon epithelial cellular protein induces oral tolerance in the experimental model of colitis by trinitrobenzene sulfonic acid. J Lab and Clin 2001; 138:257–269.CrossRefGoogle Scholar
  14. 14.
    Hollander GA, Simpson SJ, Mozoguchi E et al. Severe colitis in mice with aberrant thymic selection. Immunity 1995; 3:27–38.PubMedCrossRefGoogle Scholar
  15. 15.
    Inoue N, Watanabe M, Sato T et al. Restricted VH gene usage in lamina propria B-cells producing anticolon antibody from patients with ulcerative colitis. Gastroenterology 2001; 121:15–23.PubMedCrossRefGoogle Scholar
  16. 16.
    Das KM, Dubin R, Nagai T. Isolation and characterization of colonic tissue bound antibodies from patients with idiopathic ulcerative colitis. Proc Natl Acad Sci (USA) 1978; 75:4528–4532.CrossRefGoogle Scholar
  17. 17.
    Takahashi F, Das KM. Isolation and characterization of a colonic autoantigen specifically recognized by colon tissue-bound IgG from idiopathic ulcerative colitis. J Clin Invest 1985; 76:311–318.PubMedCrossRefGoogle Scholar
  18. 18.
    Halstensen TS, Mollnes TE, Barred P et al. Surface epithelium-related activation of complement differs in Crohn’s disease and ulcerative colitis. Gut 1992; 33:902–908.PubMedCrossRefGoogle Scholar
  19. 19.
    Halstensen TS, Mollnes TE, Garred P et al. Epithelial deposition of immunoglobulin G1 and activated complement (C3b and terminal complement complex) in ulcerative colitis. Gastroenterology 1990; 98:1264–1271.PubMedGoogle Scholar
  20. 20.
    Halstensen TS, Das KM, Brandtzaeg P. Epithelial deposits of immunoglobulin G1 and activated complement colocalize with the Mr 40K colonic autoantigen in ulcerative colitis. Gut 1993; 34:650–657.PubMedCrossRefGoogle Scholar
  21. 21.
    Das KM, Dasgupta A, Mandal A et al. Autoimmunity to cytoskeletal protein tropomyosin. A clue to the pathogenetic mechanism for ulcerative colitis. J Immunol 1993; 150:2487–2493.PubMedGoogle Scholar
  22. 22.
    Lin JJC, Warren KS, Wamboldt DD. Tropomyosin isoforms in nonmuscle cells. Int Rev Cytol 1997; 170:1–38.PubMedCrossRefGoogle Scholar
  23. 23.
    Biancone L, Mandal A, Yang H et al. Production of immunoglobulin G and G1 antibodies to cytoskeletal protein by lamina propria cells in ulcerative colitis. Gastroenterology 1995; 109:3–12.PubMedCrossRefGoogle Scholar
  24. 24.
    Geng X, Biancone L, Dai HH et al. Tropomyosin isoform in intestinal mucosa: production of autoantibodies to tropomyosin isoform in ulcerative colitis. Gastroenterology 1998; 114:912–922.PubMedCrossRefGoogle Scholar
  25. 25.
    Onuma EK, Amenta PS, Ramaswamy K et al. Autoimmunity in ulcerative colitis (UC): a predominant colonic mucosal B-cell response against human tropomyosin isoform 5. Clin Exp Immunol 2000; 121:466–471.PubMedCrossRefGoogle Scholar
  26. 26.
    Kett K, Tognum TO, Brandtzaeg P. Mucosal subclass distribution of immunoglobulin G-producing cells is different in ulcerative colitis and Crohn’s disease of the colon. Gastroenterology 1987; 93:919–924.PubMedGoogle Scholar
  27. 27.
    Taniguchi M, Geng X, Glazier KD et al. Cellular immune response against tropomyosin isoform 5 in ulcerative colitis. Clin Immunol 2001; 101:1–7.CrossRefGoogle Scholar
  28. 28.
    Sakamaki S, Takayanagi N, Yoshizaki N et al. Autoantibodies against the specific epitope of human tropomyosin(s) detected by patients with ulcerative colitis show antibody dependent cell-mediated cytotoxicity against HLA-DPw9 transfected L-cell. Gut 2000; 47:236–241.PubMedCrossRefGoogle Scholar
  29. 29.
    Mizoguchi A, Mizoguchi E, Chiba C et al. Cytoskeletal imbalance and autoantibody production in T-cell receptor-α mutant mice with inflammatory bowel disease. J Exp Med 1996; 183:847–856.PubMedCrossRefGoogle Scholar
  30. 30.
    Mizoguchi A, Mozoguchi E, Chiba C et al. Role of the appendix in the development of inflammatory bowel disease in TCR alpha mutant mice. J Exp Med 1996; 184:707–715.PubMedCrossRefGoogle Scholar
  31. 31.
    Dohlman JG, Lupas A, Carson M. Long charge-rich α-helices in systemic autoantigens. Biochem Biophys Res Immunol 2001; 195:686–696.CrossRefGoogle Scholar
  32. 32.
    Mor F, Weinberger A, Cohen IR. Identification of alpha-tropomyosin as a target self-antigen in Behcer’s syndrome. Eur J Immunol 2002; 32:356–365.PubMedCrossRefGoogle Scholar
  33. 33.
    Fenderson PG, Fischetti VA, Cunningham MW. Tropomyosin shares immunologic epitopes with group A streptococcal M proteins. J Immunol 1989; 142:2475–2481.PubMedGoogle Scholar
  34. 34.
    Biancone L, Monteleone G, Marasco R et al. Autoimmunity to tropomyosin isoforms in ulcerative colitis (UC) patients and unaffected relatives. Clin Exp Immunol 1998; 113:198–205.PubMedCrossRefGoogle Scholar
  35. 35.
    Das KM, Sakamaki S, Vecchi M et al. The production and characterization of monoclonal antibodies to a human colonic antigen associated with ulcerative colitis: cellular localization of the antigen using the monoclonal antibody. J Immunol 1987; 139:77–84.PubMedGoogle Scholar
  36. 36.
    Kesari KV, Yoshizaki N, Geng X et al. Externalization of tropomyosin isoform 5 in colon epithelial cells. Clin Exp Immunol 1999; 118:219–227.PubMedCrossRefGoogle Scholar
  37. 37.
    Mirza ZK, Sastri B, Lin JJ-C et al. Autoimmunity against human tropomyosin isoforms (hTms) in ulcerative colitis: localization of specific hTms in the intestine and extraintestinal organs. Inflamm Bowel Dis 2006; 12:1036–1043.PubMedCrossRefGoogle Scholar
  38. 38.
    Das KM, Squillante L, Robertson F. An increased expression of the Mr 40,000 colonic epithelial protein in DLD-1 colon cancer cells in response to gamma interferon (γ-IFN) and tumor necrosis factor (TNF). Gastroenterology 1989; 96:A111.Google Scholar
  39. 39.
    Geng X, Liu J, Lin JJ-C et al. Gamma interferon increases surface expression and externalization of human tropomyosin isoform 5 (hTm5) in colon epithelial cells. Gastroenterology 2003; 124:A157.CrossRefGoogle Scholar
  40. 40.
    Tatar E, Cohen HD, Geng X et al. Human tropomyosin isoform 5 (hTm5) expression is increased in the colonic mucosa from patients with active ulcerative colitis. Gastroenterology 2002; 122:A531.CrossRefGoogle Scholar
  41. 41.
    Yantiss RK, Das KM, Farraye F et al. Alterations in the immuno histochemical expression of Das-1 and CG-3 in colonic mucosal biopsy specimens help distinguish ulcerative colitis from Crohn’s disease and from other forms of colotis. Am J Surg Pathol, In Press.Google Scholar
  42. 42.
    Das KM, Vecchi M, Sakamaki S. A shared and unique epitope(s) on human colon, skin and biliary epithelium detected by a monoclonal antibody. Gastroenterology 1990; 98:464–469.PubMedGoogle Scholar
  43. 43.
    Bhagat S, Das KM. A shared and unique peptide in human colon, eye and joint detected by a novel monoclonal antibody. Gastroenterology 1994; 107:103–108.PubMedGoogle Scholar
  44. 44.
    Das KM. Relationships of extracolonic involvement in inflammatory bowel disease: New insights into autoimmune pathogenesis. Dig Dis Sci 1999; 44:1–13.PubMedCrossRefGoogle Scholar
  45. 45.
    Karrar A, Broome U, Sodergren T et al. Biliary epithelial cell antibodies link adaptive and innate immune responses in primary sclerosing cholangitis. Gastroenterology 2007; 132:1504–1514.PubMedCrossRefGoogle Scholar
  46. 46.
    Adams DH, Eksteen B. Aberrant homing of mucosal T-cells and extraintestinal manifestations of inflammatory bowel disease. Nat Rev Immunol 2006; 6:244–251.PubMedCrossRefGoogle Scholar
  47. 47.
    Mandal A, Dasgupta A, Jeffers L et al. Autoantibodies in sclerosing cholangitis against a shared epitope in biliary and colon epithelium. Gastroenterology 1994; 106:185–192.PubMedGoogle Scholar
  48. 48.
    Monsen U, Sorstad J, Hellers G et al. Extracolonic diagnoses in ulcerative colitis: An epidemiological study. Am J Gastroenterol 1990; 85:711–716.PubMedGoogle Scholar
  49. 49.
    Botros N, Pickover L, Das KM. Image of the month. Gastroenterology 2000; 118:654.PubMedCrossRefGoogle Scholar
  50. 50.
    Ebert EC, Geng X, Lin J et al. Autoantibodies against human tropomyosin isoform 5 in ulcerative colitis destroys colonic epithelial cells through antibody and complement-mediated lysis. Cell Immunol 2006; 244:43–49.PubMedCrossRefGoogle Scholar
  51. 51.
    Elson CJ, Barker RN, Thompson SJ et al. Immunologically ignorant autoreactive T-cells, epitope spreading and repertoire limitation. Immunol Today 1995; 16:71–76.PubMedCrossRefGoogle Scholar
  52. 52.
    Biancone L, Palmieri G, Lombardi A et al. Tropomyosin expression in the ileal pouch: a relationship with the development of pouchitis in ulcerative colitis. Am J Gastroenterol 2003; 98:2719–2726.PubMedCrossRefGoogle Scholar
  53. 53.
    Luo Y, Frey EA, Pfuztzner RA et al. Crystal structure of enteropathogenetic Escherichia Coli. Intimin-receptor complex. Nature 2000; 405:1077–1077.CrossRefGoogle Scholar
  54. 54.
    Vallance BA, Finlay BB. Exploitation of host cells by enteropathogenic Escherichia Coli. Proc Natl Acad Sci USA 2000; 97:8799–8806.PubMedCrossRefGoogle Scholar
  55. 55.
    Propato A, Cutrona G, Francavilla V et al. Apoptotic cells overexpress vinculin and induce vinculin-specific cytotoxic T-cell cross priming. Nat Med 2001; 7:807–813.PubMedCrossRefGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2008

Authors and Affiliations

  1. 1.Division of Gastroenterology and Hepatology, Department of Medicine, Crohn’s and Colitis Center of New JerseyUMDNJ-Robert Wood Johnson Medical SchoolNew BrunswickUSA

Personalised recommendations